Form 4: Intuitive Surgical Executive Exercises Options and Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Robert DeSantis, EVP & Chief Strategy & Corp Op at Intuitive Surgical, executed stock options and sold shares of common stock on March 13, 2025, according to a pre-arranged trading plan.
Summary
- On March 13, 2025, Robert DeSantis, EVP & Chief Strategy & Corp Op at Intuitive Surgical Inc. (ISRG), exercised non-qualified stock options to acquire common stock.
- DeSantis then sold these shares on the same day at prices ranging from $498.71 to $500 per share.
- These transactions were executed under a pre-arranged trading plan that complies with SEC Rule 10b5-1, which is set to expire on December 12, 2025.
- The exercise prices for the options ranged from $208.9 to $347.4167.
- Following these transactions, DeSantis directly owns 13,488 shares of Intuitive Surgical common stock.
- The sales involved multiple transactions at a price of $498.71, and one transaction at $500.
Sentiment
Score: 5
Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, suggesting a neutral sentiment.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock sales.
Future Outlook
The executive's future transactions may continue under the existing 10b5-1 trading plan until its expiration on December 12, 2025.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation practices, including stock options and sales, are common across the medical device industry.
- Companies like Medtronic, Stryker, and Johnson & Johnson also utilize stock options as part of their executive compensation packages.
- The vesting schedules and exercise prices are generally in line with industry norms for incentivizing long-term performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares.
- The executive's actions are unlikely to significantly affect employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/10/2023 | Date used to measure six-month anniversary for vesting of some stock options. |
| 08/10/2023 | Date used to measure one-month anniversary for vesting of some stock options. |
| 08/28/2029 | Expiration date of some non-qualified stock options. |
| 02/27/2030 | Expiration date of some non-qualified stock options. |
| 08/09/2030 | Expiration date of some non-qualified stock options. |
| 02/26/2031 | Expiration date of some non-qualified stock options. |
| 08/26/2031 | Expiration date of some non-qualified stock options. |
| 03/13/2025 | Date of the stock option exercise and sale transactions. |
| 03/14/2025 | Date of the SEC Form 4 filing. |
| 12/12/2025 | Expiration date of the 10b5-1 trading plan. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.